BROOMFIELD, Colo., Feb. 17 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today it is a SILVER level sponsor of the 2009 International Conference on Alzheimer's Disease (ICAD). The annual conference, put on by the Alzheimer's Association, is the world's leading forum on dementia research. ICAD 2009 will take place July 11-16 in Vienna, Austria.
"Alzheimer's is a progressive and fatal disease that significantly impacts millions of patients, their families and caregivers," said Steve Orndorff, Ph.D., Accera's founder and CEO. "As a company focused on CNS disorders, Accera is committed to improving the care and quality of life of Alzheimer's patients who are in need of innovative, safe, new therapeutic options. By supporting ICAD we are joining the Alzheimer's Association in their quest to advance research, care and support for AD."
In the U.S., 5.2 million people are living with AD and it has become the sixth leading cause of death. There is currently no cure for AD and there is a tremendous need for new and innovative therapies.
ICAD 2009 is expected to draw approximately 5,000 researchers, clinicians and neurologists from around the world to engage in a multidisciplinary exchange of ideas. The international sharing of research looks to advance prevention methods, treatments and a cure for AD.
The Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) is the largest gathering of international leaders in Alzheimer research and care. At ICAD, researchers from around the world share groundbreaking information and resources on the cause, diagnosis, treatment and prevention of Alzheimer's and related disorders. As a part of the Association's research program, ICAD serves as a catalyst for generating new knowledge about dementia and fostering a vital, colle
|SOURCE Accera, Inc.|
Copyright©2009 PR Newswire.
All rights reserved